Elacyt (elacytarabine) / Karo Pharma - LARVOL DELTA

Lipid Droplet-Targeted Biomimetic Liposomes Potentiate Chemo-Ferroptosis Therapy in Leukemia. (PubMed, Adv Mater) - "Based on these findings, we developed a biomimetic liposome (REM@HLipo) co-encapsulating RSL3 (a ferroptosis inducer), elacytarabine (a cytarabine prodrug), and metformin (an LD disruptor) to enhance chemo-ferroptosis therapy against leukemia. Moreover, REM@HLipo significantly reduces leukemia stem cell populations in AML models. This study presents a novel chemo-ferroptosis therapeutic regimen for leukemia management."

Journal • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Effects of nucleoside analogues, lipophilic prodrugs and elaidic acids on core signaling pathways in cancer cells. (PubMed, Nucleosides Nucleotides Nucleic Acids) - "Nucleoside analogs such as gemcitabine (GEM; dFdC) and cytarabine (Ara-C) require nucleoside transporters to enter cells, and deficiency in equilibrative nucleoside transporter 1 (ENT1) can lead to resistance to these drugs. In A549 cells treatment with Ara-C, CP-4055 and EA-4126 decreased the p-P38/P38 after 6 hr. The findings suggest that both parent drugs, prodrugs, and the EA chain influence cell survival and signaling pathways."

Journal • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • SLC29A1

"We should probably do keratinocytic marker (EMA) vs melacytic markers vs CEA for adnexal CA. One of our dermpath attendings usually get a CK20 to light up the merkel cells scattered in the adnexal tumors (to distinguish it from SCC/BCC)." (@debpratik)